Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder
Deepak Cyril D’Souza, Shariful A. Syed, L. Taylor Flynn, et al.
Neuropsychopharmacology (2022) Vol. 47, Iss. 10, pp. 1854-1862
Open Access | Times Cited: 100

Showing 26-50 of 100 citing articles:

Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial
Ellen James, David Erritzøe, Tiffanie Benway, et al.
Frontiers in Psychiatry (2024) Vol. 14
Open Access | Times Cited: 6
The economics of psychedelic-assisted therapies: A research agenda
Elliot Marseille, Stefano Bertozzi, James G. Kahn
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 25
A Brief Historical Overview of Psychedelic Research
Mark A. Geyer
Biological Psychiatry Cognitive Neuroscience and Neuroimaging (2023) Vol. 9, Iss. 5, pp. 464-471
Closed Access | Times Cited: 14
Psychedelic Therapy: A Primer for Primary Care Clinicians—N,N-Dimethyltryptamine and Ayahuasca
Kenneth Shinozuka, Burton J. Tabaac, Alejandro Arenas, et al.
American Journal of Therapeutics (2024) Vol. 31, Iss. 2, pp. e112-e120
Closed Access | Times Cited: 5
Therapeutic modulation of the kynurenine pathway in severe mental illness and comorbidities: A potential role for serotonergic psychedelics
Antonella Campanale, Antonio Inserra, Stefano Comai
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2024) Vol. 134, pp. 111058-111058
Open Access | Times Cited: 5
Psychedelic Therapy: A Primer for Primary Care Clinicians—Historical Perspective and Overview
Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas, et al.
American Journal of Therapeutics (2024) Vol. 31, Iss. 2, pp. e97-e103
Closed Access | Times Cited: 4
Neurochemical and Neurophysiological Effects of Intravenous Administration ofN,N-dimethyltryptamine in Rats
Nicolas G. Glynos, Emma R. Huels, Amanda Nelson, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 4
Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties
Mazen A. Atiq, Matthew Baker, Jennifer L. Vande Voort, et al.
Psychopharmacology (2024)
Open Access | Times Cited: 4
Autonomic nervous system activity correlates with peak experiences induced by DMT and predicts increases in well-being
Valérie Bonnelle, Amanda Feilding, Fernando E. Rosas, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 10, pp. 887-896
Open Access | Times Cited: 4
Exploring DMT: Endogenous Role and Therapeutic Potential
J. Schimmelpfennig, Kamila Jankowiak-Siuda
Neuropharmacology (2025), pp. 110314-110314
Open Access
Clinical Pharmacokinetics of N,N-Dimethyltryptamine (DMT): A Systematic Review and Post-hoc Analysis
Katelijne V. van der Heijden, Marije E. Otto, Jan W. Schoones, et al.
Clinical Pharmacokinetics (2025)
Open Access
Liquid chromatography–tandem mass spectrometry method for the bioanalysis of N,N-dimethyltryptamine (DMT) and its metabolites DMT-N-oxide and indole-3-acetic acid in human plasma
Dino Luethi, Karolina E. Kolaczynska, Severin B. Vogt, et al.
Journal of Chromatography B (2022) Vol. 1213, pp. 123534-123534
Open Access | Times Cited: 18
Molecular Pathways of the Therapeutic Effects of Ayahuasca, a Botanical Psychedelic and Potential Rapid-Acting Antidepressant
Giordano Novak Rossi, Lorena T. L. Guerra, Glen B. Baker, et al.
Biomolecules (2022) Vol. 12, Iss. 11, pp. 1618-1618
Open Access | Times Cited: 17
Psilocybin and Other Classic Psychedelics in Depression
David Nutt, Joseph Peill, Brandon Weiss, et al.
Current topics in behavioral neurosciences (2023), pp. 149-174
Closed Access | Times Cited: 9
Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial
Marcelo Falchi, Isabel Wießner, Sérgio Ruschi Bergamachi Silva, et al.
European Neuropsychopharmacology (2023) Vol. 80, pp. 27-35
Closed Access | Times Cited: 9
Ayahuasca and Dimethyltryptamine Adverse Events and Toxicity Analysis: A Systematic Thematic Review
Eleanor White, Tom Kennedy, Simon Ruffell, et al.
International Journal of Toxicology (2024) Vol. 43, Iss. 3, pp. 327-339
Open Access | Times Cited: 3
Novel extended-release transdermal formulations of the psychedelic N,N-dimethyltryptamine (DMT)
Christopher G. Witowski, M. Hess, N. Jones, et al.
European Journal of Pharmaceutical Sciences (2024) Vol. 199, pp. 106803-106803
Open Access | Times Cited: 3
Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine in human subjects: a systematic review of clinical trials
Aleksander Kwaśny, Alina Wilkowska, Wiesław Jerzy Cubała
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 3
The psychedelic effects of cannabis: A review of the literature
David Isaac Wolinsky, Frederick S. Barrett, Ryan G. Vandrey
Journal of Psychopharmacology (2023) Vol. 38, Iss. 1, pp. 49-55
Closed Access | Times Cited: 8
Psychedelics for treatment resistant depression: are they game changers?
Michail Kalfas, Rosie H. Taylor, Dimosthenis Tsapekos, et al.
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 18, pp. 2117-2132
Open Access | Times Cited: 8
Therapeutic frameworks in integration sessions in substance‐assisted psychotherapy: A systematised review
Sascha Thal, Paris Baker, Jonathon Marinis, et al.
Clinical Psychology & Psychotherapy (2023) Vol. 31, Iss. 1
Open Access | Times Cited: 8
Hallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder
Mary G. Hornick, Ashley Stefanski
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 7
Therapeutic potential of psychedelics: History, advancements, and unexplored frontiers
Juliana Marino Maia, Bruna Stefane Alves de Oliveira, Luiz G.S. Branco, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2024) Vol. 131, pp. 110951-110951
Closed Access | Times Cited: 2
The Clinical Potential of Dimethyltryptamine: Breakthroughs into the Other Side of Mental Illness, Neurodegeneration, and Consciousness
Frankie A. Colosimo, Philip Borsellino, Reese I. Krider, et al.
Psychoactives (2024) Vol. 3, Iss. 1, pp. 93-122
Open Access | Times Cited: 2
EMBARK Psychedelic Therapy for Depression
Bill Brennan, Alex Belser
(2024)
Closed Access | Times Cited: 2

Scroll to top